Short Interest in Fresenius SE & Co. (OTCMKTS:FSNUY) Increases By 113.3%

Key Points

• Short interest in Fresenius SE & Co. saw a remarkable increase of 113.3% in September, rising from 23,300 shares to 49,700 shares as of September 15th.
• The company reported earnings of $0.24 per share for the previous quarter, exceeding analysts' expectations of $0.22 and generating $6.48 billion in revenue.
• Wall Street analysts currently have an average rating of "Buy" for Fresenius SE & Co., with one analyst rating it as a Strong Buy and two as Buy.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 49,700 shares, a growth of 113.3% from the August 31st total of 23,300 shares. Based on an average daily trading volume, of 52,500 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily trading volume, of 52,500 shares, the days-to-cover ratio is presently 0.9 days.

Fresenius SE & Co. Price Performance

OTCMKTS:FSNUY traded up $0.09 during trading hours on Friday, hitting $13.91. 56,354 shares of the stock traded hands, compared to its average volume of 39,560. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.49. Fresenius SE & Co. has a 1 year low of $8.48 and a 1 year high of $14.24. The company has a market cap of $31.08 billion, a price-to-earnings ratio of 26.25 and a beta of 0.83. The stock has a 50 day moving average price of $13.43 and a 200 day moving average price of $12.37.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.02. The firm had revenue of $6.48 billion for the quarter, compared to analysts' expectations of $5.83 billion. Fresenius SE & Co. had a net margin of 5.09% and a return on equity of 9.33%. Sell-side analysts forecast that Fresenius SE & Co. will post 0.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy".

About Fresenius SE & Co.

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.